Articles

GHO Capital and CBC Group Merge: A New Era in Healthcare Investment

GHO Capital and CBC Group's merger could reshape healthcare investments. Discover the implications for the pharmaceutical industry.

Regulatory Education for 2026: Key Insights Ahead of the Event

As we approach the Regulatory Education event in May 2026, industry professionals are eager to understand the implications for regulatory strategies. This article outlines key takeaways and what to expect from the event.

Acceleron and Westlake Launch New IPF Biotech Venture

Acceleron and Westlake are initiating a new biotech focused on idiopathic pulmonary fibrosis (IPF). This article explores the implications for the pharmaceutical industry.

Paragon's Reverse Merger: Implications for Migraine Drug Development

Paragon's latest reverse merger signals a strategic shift in migraine drug development. This article explores its implications for the pharmaceutical industry.

BBSW AI Solution: Key Insights from the 2026 Event

The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.

Pharma Manufacturing World 2026: Key Insights and Expectations

As Pharma Manufacturing World 2026 approaches, key insights and expectations are emerging. This article previews the event's agenda, key players, and potential catalysts.

Atara Bounces Back with FDA Approval in Oncology

Atara has received FDA approval for its oncology treatment, marking a significant turnaround for the company. This article analyzes the implications for investors and BD teams.

ReDI 2026 Conference: Key Insights for B2B Readers

The ReDI 2026 Conference promises to be a pivotal event for B2B stakeholders in the pharma industry. Here’s what you need to know ahead of the conference.

Drugmakers Tighten IP Protections Amid China Competition

As competition from China intensifies, drugmakers are increasingly safeguarding their intellectual property. This article explores the implications for the pharmaceutical industry.

Migraine Drugmaker Goes Public: Insights on Reverse Merger

A migraine drugmaker is set to enter public markets via a reverse merger, raising questions about its future impact on the pharmaceutical landscape.

Congressional Democrats Push to End Medicare AI Prior Authorization Pilot

Congressional Democrats are attempting to force a vote to terminate the Medicare AI prior authorization pilot. This move could have significant implications for the pharmaceutical industry.

Florida Hospitals Secure $8 Billion in Extra Medicaid Funds

Florida hospitals have secured $8 billion in additional Medicaid funding, significantly impacting the healthcare sector. This article explores the implications for pharmaceutical teams and investors.

STAT+: Pioneering Trial for Treating Genetic Disease Before Birth

This article discusses the upcoming FDA trial for in-utero gene therapy targeting genetic diseases, highlighting its significance for the pharmaceutical industry.

Palvella's Pivotal Rare-Disease Data and Financial Outlook

Palvella (NASDAQ: PVLA) reveals pivotal data in rare diseases and boasts a robust cash runway of $274M, signaling significant investment potential.

Ebola: Perspectives from a Doctor and Patient

This article shares insights from a doctor who experienced Ebola firsthand, highlighting the need for greater awareness of the challenges faced by African healthcare workers.

BBSW AI Solution 2026: Key Insights and Highlights

The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.

Streamlined R&D at Novo Nordisk: Insights from Research Chief Petersen

Novo Nordisk's research chief, Petersen, discusses how streamlined R&D processes enhance drug discovery efficiency, impacting the pharmaceutical landscape.

Clinical Research Patient 2026: What to Expect

The Clinical Research Patient event in 2026 promises to be a pivotal gathering for industry professionals. Here's what you need to know ahead of time.

The Current Landscape of Consumer Health: Insights and Implications

This article delves into the evolving landscape of consumer health, highlighting key trends and their implications for pharmaceutical businesses.

23andMe Connects DNA Data with Medical Records: Implications for Pharma

23andMe is now connecting users’ DNA data with their medical records, raising significant implications for the pharmaceutical sector. This article explores the potential impacts and opportunities.